CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
53.74 USD
-0.59%
Market Closed
Updated:
Jun 3, 2024
CRISPR Therapeutics AG
Operating Expenses
|
CRISPR Therapeutics AG
Operating Expenses Peer Comparison
Comparables:
ADCT
ACIU
BSLN
IDIA
KURN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Expenses
-$570.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Expenses
-$233m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Expenses
-CHf70.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Expenses
-CHf111.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Expenses
-CHf688.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Expenses
-CHf37.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
See Also
What is CRISPR Therapeutics AG's Operating Expenses?
Operating Expenses
-570.3m
USD
-570.3m
USD
Based on the financial report for Mar 31, 2024, CRISPR Therapeutics AG's Operating Expenses amounts to -570.3m USD.
What is CRISPR Therapeutics AG's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-26%
-26%
Over the last year, the Operating Expenses growth was 14%. The average annual Operating Expenses growth rates for CRISPR Therapeutics AG have been -13% over the past three years , -26% over the past five years .
You don't have any saved screeners yet
